![]() Pompe Disease Therapeutics Market Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Treatment Type (Drugs, Enzyme Replacement Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy), By Route of Administration (Oral, Parenteral), By End User (Hospitals & Speciality Clinics, Other), By Region, & Competition, 2020-2030F
Global Pompe Disease Therapeutics Market was valued at USD 1.50 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.40% through 2030. The Global Pomp... もっと見る
SummaryGlobal Pompe Disease Therapeutics Market was valued at USD 1.50 Billion in 2024 and is anticipated to project steady growth in the forecast period with a CAGR of 4.40% through 2030. The Global Pompe Disease Therapeutics Market is a rapidly evolving segment within the rare disease and orphan drug industry, driven by scientific advancements and increasing investment in innovative therapies. Pompe disease, or glycogen storage disease type II, is a rare lysosomal disorder caused by the deficiency of acid alpha-glucosidase (GAA), leading to glycogen accumulation in muscle tissues. This results in progressive muscle weakness and severe respiratory complications, necessitating targeted therapeutic interventions.The market is primarily shaped by enzyme replacement therapies (ERTs) such as Myozyme (alglucosidase alfa), Lumizyme, and the more recent Nexviazyme (avalglucosidase alfa), which offer improved glycogen clearance and clinical outcomes. Additionally, the approval of Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat) in 2023 has expanded treatment options for patients, particularly those with late-onset Pompe disease (LOPD) who exhibit suboptimal responses to conventional ERTs. Despite these advancements, market penetration is constrained by high treatment costs and limited newborn screening programs, leading to delayed diagnoses and disease progression. However, gene therapy and next-generation therapeutics are emerging as potential breakthroughs, with ongoing clinical trials aiming to provide more durable and cost-effective treatment alternatives. Key Market Drivers Increased Disease Awareness and Diagnosis Pompe disease, often considered a rare or orphan disease, historically suffered from a lack of recognition and understanding. Pompe disease is a complex, multisystem genetic disorder with a prevalence of approximately 1 in 40,000 individuals in the United States. Increasing awareness of this rare condition is crucial, as early diagnosis and timely intervention can significantly improve patient outcomes and quality of life. Efforts to enhance disease recognition are being driven by medical institutions, patient advocacy groups, and biotech companies focused on expanding access to diagnostics and treatment. Newborn screening programs, physician education initiatives, and targeted awareness campaigns are playing a pivotal role in identifying patients earlier and facilitating access to advanced therapies. Patients faced delayed or misdiagnoses, leading to prolonged suffering and a dearth of effective treatments. Advocacy groups dedicated to Pompe disease have played a pivotal role in driving disease awareness. These organizations tirelessly work to raise public awareness, educate healthcare professionals, and provide support to affected individuals and their families. By leveraging social media, organizing awareness campaigns, and collaborating with healthcare institutions, these groups have succeeded in putting Pompe disease on the radar. The evolution of diagnostic technologies is another catalyst for increased disease awareness. Cutting-edge tools such as genetic testing and biomarker identification have revolutionized the diagnostic process. Physicians can now identify Pompe disease more accurately and swiftly, enabling timely intervention and treatment initiation. This, in turn, has elevated the importance of early diagnosis in improving patient outcomes. Key Market Challenges Limited Disease Awareness and Late Diagnosis One of the foremost challenges in the Pompe Disease Therapeutics Market is the limited awareness of the disease itself, leading to delayed or missed diagnoses. Pompe disease is considered a rare condition, making it less well-known among healthcare professionals and the general public. This lack of awareness often results in late-stage diagnoses, which can significantly impact treatment outcomes. Pompe disease's rarity, with an estimated incidence of 1 in 40,000 to 1 in 300,000 births, contributes to its obscurity. As healthcare professionals encounter rare diseases less frequently, the likelihood of prompt recognition and diagnosis diminishes. Pompe disease presents with symptoms that can overlap with those of other more common conditions, such as muscle weakness and respiratory problems. This lack of distinctiveness can lead to misdiagnoses or a failure to consider Pompe disease as a potential cause. Key Market Trends Personalized Medicine and Precision Therapies One of the most significant trends in the Pompe Disease Therapeutics Market is the shift towards personalized medicine and precision therapies. Traditional treatment approaches often took a one-size-fits-all approach, but advancements in genetics and diagnostics have paved the way for tailored treatments that address the specific genetic mutations of individual patients. Advances in genetic research have provided insights into the precise genetic mutations that cause Pompe disease. This knowledge allows for the development of therapies that target the specific genetic defects in individual patients, maximizing treatment efficacy. Pharmaceutical companies are investing in innovative approaches, such as gene therapy and RNA-based therapies, that can be customized to target specific genetic mutations. These therapies hold the potential to correct the underlying genetic causes of Pompe disease. Advanced diagnostic tools, including genetic testing and biomarker identification, enable healthcare providers to identify the specific genetic mutations in Pompe disease patients. This information guides treatment decisions, ensuring that therapies are tailored to each patient's unique genetic profile. Key Market Players • Genzyme Corp • Amicus Therapeutics Inc • Valerion Therapeutics LLC • Audentes Therapeutics Inc • Actus Therapeutics Inc • BioMarin Pharmaceutical Inc • EpiVax inc • Oxyrane Co Ltd. • Sangamo BioSciences Inc • Avrobio Inc • Spark Therapeutics Inc Report Scope: In this report, the Global Pompe Disease Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: • Pompe Disease Therapeutics Market, By Treatment Type: o Drugs o Enzyme Replacement Therapy o Physical Therapy o Chaperone-Advanced Replacement Therapy • Pompe Disease Therapeutics Market, By Route of Administration: o Oral o Parenteral • Pompe Disease Therapeutics Market, By End User: o Hospitals & Speciality Clinics o Other • Pompe Disease Therapeutics Market, By Region: o North America § United States § Canada § Mexico o Europe § France § United Kingdom § Italy § Germany § Spain o Asia-Pacific § China § India § Japan § Australia § South Korea o South America § Brazil § Argentina § Colombia o Middle East & Africa § South Africa § Saudi Arabia § UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Pompe Disease Therapeutics Market. Available Customizations: Global Pompe Disease Therapeutics market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information • Detailed analysis and profiling of additional market players (up to five). Table of Contents1. Product Overview1.1. Market Definition 1.2. Scope of the Market 1.2.1. Markets Covered 1.2.2. Years Considered for Study 1.2.3. Key Market Segmentations 2. Research Methodology 2.1. Objective of the Study 2.2. Baseline Methodology 2.3. Key Industry Partners 2.4. Major Association and Secondary Sources 2.5. Forecasting Methodology 2.6. Data Triangulation & Validation 2.7. Assumptions and Limitations 3. Executive Summary 3.1. Overview of the Market 3.2. Overview of Key Market Segmentations 3.3. Overview of Key Market Players 3.4. Overview of Key Regions/Countries 3.5. Overview of Market Drivers, Challenges, Trends 4. Voice of Customer 5. Pompe Disease Therapeutics Market Outlook 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Treatment Type (Drugs, Enzyme Replacement Therapy, Physical Therapy, Chaperone-Advanced Replacement Therapy) 5.2.2. By Route of Administration (Oral, Parenteral) 5.2.3. By End User (Hospitals & Speciality Clinics, Other) 5.2.4. By Region 5.2.5. By Company (2024) 5.3. Market Map 6. North America Pompe Disease Therapeutics Market Outlook 6.1. Market Size & Forecast 6.1.1. By Value 6.2. Market Share & Forecast 6.2.1. By Treatment Type 6.2.2. By Route of Administration 6.2.3. By End User 6.2.4. By Country 6.3. North America: Country Analysis 6.3.1. United States Pompe Disease Therapeutics Market Outlook 6.3.1.1. Market Size & Forecast 6.3.1.1.1. By Value 6.3.1.2. Market Share & Forecast 6.3.1.2.1. By Treatment Type 6.3.1.2.2. By Route of Administration 6.3.1.2.3. By End User 6.3.2. Canada Pompe Disease Therapeutics Market Outlook 6.3.2.1. Market Size & Forecast 6.3.2.1.1. By Value 6.3.2.2. Market Share & Forecast 6.3.2.2.1. By Treatment Type 6.3.2.2.2. By Route of Administration 6.3.2.2.3. By End User 6.3.3. Mexico Pompe Disease Therapeutics Market Outlook 6.3.3.1. Market Size & Forecast 6.3.3.1.1. By Value 6.3.3.2. Market Share & Forecast 6.3.3.2.1. By Treatment Type 6.3.3.2.2. By Route of Administration 6.3.3.2.3. By End User 7. Europe Pompe Disease Therapeutics Market Outlook 7.1. Market Size & Forecast 7.1.1. By Value 7.2. Market Share & Forecast 7.2.1. By Treatment Type 7.2.2. By Route of Administration 7.2.3. By End User 7.2.4. By Country 7.3. Europe: Country Analysis 7.3.1. Germany Pompe Disease Therapeutics Market Outlook 7.3.1.1. Market Size & Forecast 7.3.1.1.1. By Value 7.3.1.2. Market Share & Forecast 7.3.1.2.1. By Treatment Type 7.3.1.2.2. By Route of Administration 7.3.1.2.3. By End User 7.3.2. United Kingdom Pompe Disease Therapeutics Market Outlook 7.3.2.1. Market Size & Forecast 7.3.2.1.1. By Value 7.3.2.2. Market Share & Forecast 7.3.2.2.1. By Treatment Type 7.3.2.2.2. By Route of Administration 7.3.2.2.3. By End User 7.3.3. Italy Pompe Disease Therapeutics Market Outlook 7.3.3.1. Market Size & Forecast 7.3.3.1.1. By Value 7.3.3.2. Market Share & Forecast 7.3.3.2.1. By Treatment Type 7.3.3.2.2. By Route of Administration 7.3.3.2.3. By End User 7.3.4. France Pompe Disease Therapeutics Market Outlook 7.3.4.1. Market Size & Forecast 7.3.4.1.1. By Value 7.3.4.2. Market Share & Forecast 7.3.4.2.1. By Treatment Type 7.3.4.2.2. By Route of Administration 7.3.4.2.3. By End User 7.3.5. Spain Pompe Disease Therapeutics Market Outlook 7.3.5.1. Market Size & Forecast 7.3.5.1.1. By Value 7.3.5.2. Market Share & Forecast 7.3.5.2.1. By Treatment Type 7.3.5.2.2. By Route of Administration 7.3.5.2.3. By End User 8. Asia-Pacific Pompe Disease Therapeutics Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Treatment Type 8.2.2. By Route of Administration 8.2.3. By End User 8.2.4. By Country 8.3. Asia-Pacific: Country Analysis 8.3.1. China Pompe Disease Therapeutics Market Outlook 8.3.1.1. Market Size & Forecast 8.3.1.1.1. By Value 8.3.1.2. Market Share & Forecast 8.3.1.2.1. By Treatment Type 8.3.1.2.2. By Route of Administration 8.3.1.2.3. By End User 8.3.2. India Pompe Disease Therapeutics Market Outlook 8.3.2.1. Market Size & Forecast 8.3.2.1.1. By Value 8.3.2.2. Market Share & Forecast 8.3.2.2.1. By Treatment Type 8.3.2.2.2. By Route of Administration 8.3.2.2.3. By End User 8.3.3. Japan Pompe Disease Therapeutics Market Outlook 8.3.3.1. Market Size & Forecast 8.3.3.1.1. By Value 8.3.3.2. Market Share & Forecast 8.3.3.2.1. By Treatment Type 8.3.3.2.2. By Route of Administration 8.3.3.2.3. By End User 8.3.4. South Korea Pompe Disease Therapeutics Market Outlook 8.3.4.1. Market Size & Forecast 8.3.4.1.1. By Value 8.3.4.2. Market Share & Forecast 8.3.4.2.1. By Treatment Type 8.3.4.2.2. By Route of Administration 8.3.4.2.3. By End User 8.3.5. Australia Pompe Disease Therapeutics Market Outlook 8.3.5.1. Market Size & Forecast 8.3.5.1.1. By Value 8.3.5.2. Market Share & Forecast 8.3.5.2.1. By Treatment Type 8.3.5.2.2. By Route of Administration 8.3.5.2.3. By End User 9. South America Pompe Disease Therapeutics Market Outlook 9.1. Market Size & Forecast 9.1.1. By Value 9.2. Market Share & Forecast 9.2.1. By Treatment Type 9.2.2. By Route of Administration 9.2.3. By End User 9.2.4. By Country 9.3. South America: Country Analysis 9.3.1. Brazil Pompe Disease Therapeutics Market Outlook 9.3.1.1. Market Size & Forecast 9.3.1.1.1. By Value 9.3.1.2. Market Share & Forecast 9.3.1.2.1. By Treatment Type 9.3.1.2.2. By Route of Administration 9.3.1.2.3. By End User 9.3.2. Argentina Pompe Disease Therapeutics Market Outlook 9.3.2.1. Market Size & Forecast 9.3.2.1.1. By Value 9.3.2.2. Market Share & Forecast 9.3.2.2.1. By Treatment Type 9.3.2.2.2. By Route of Administration 9.3.2.2.3. By End User 9.3.3. Colombia Pompe Disease Therapeutics Market Outlook 9.3.3.1. Market Size & Forecast 9.3.3.1.1. By Value 9.3.3.2. Market Share & Forecast 9.3.3.2.1. By Treatment Type 9.3.3.2.2. By Route of Administration 9.3.3.2.3. By End User 10. Middle East and Africa Pompe Disease Therapeutics Market Outlook 10.1. Market Size & Forecast 10.1.1. By Value 10.2. Market Share & Forecast 10.2.1. By Treatment Type 10.2.2. By Route of Administration 10.2.3. By End User 10.2.4. By Country 10.3. MEA: Country Analysis 10.3.1. South Africa Pompe Disease Therapeutics Market Outlook 10.3.1.1. Market Size & Forecast 10.3.1.1.1. By Value 10.3.1.2. Market Share & Forecast 10.3.1.2.1. By Treatment Type 10.3.1.2.2. By Route of Administration 10.3.1.2.3. By End User 10.3.2. Saudi Arabia Pompe Disease Therapeutics Market Outlook 10.3.2.1. Market Size & Forecast 10.3.2.1.1. By Value 10.3.2.2. Market Share & Forecast 10.3.2.2.1. By Treatment Type 10.3.2.2.2. By Route of Administration 10.3.2.2.3. By End User 10.3.3. UAE Pompe Disease Therapeutics Market Outlook 10.3.3.1. Market Size & Forecast 10.3.3.1.1. By Value 10.3.3.2. Market Share & Forecast 10.3.3.2.1. By Treatment Type 10.3.3.2.2. By Route of Administration 10.3.3.2.3. By End User 11. Market Dynamics 11.1. Drivers 11.2. Challenges 12. Market Trends & Developments 12.1. Recent Developments 12.2. Product Launches 12.3. Mergers & Acquisitions 13. Global Pompe Disease Therapeutics Market: SWOT Analysis 14. Competitive Landscape 14.1. Genzyme Corp 14.1.1. Business Overview 14.1.2. Product & Service Offerings 14.1.3. Recent Developments 14.1.4. Financials (If Listed) 14.1.5. Key Personnel 14.1.6. SWOT Analysis 14.2. Amicus Therapeutics Inc 14.3. Valerion Therapeutics LLC 14.4. Audentes Therapeutics Inc 14.5. Actus Therapeutics Inc 14.6. BioMarin Pharmaceutical Inc 14.7. EpiVax inc 14.8. Oxyrane Co Ltd. 14.9. Sangamo BioSciences Inc 14.10.Avrobio Inc 14.11.Spark Therapeutics Inc. 15. Strategic Recommendations 16. About Us & Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポート
TechSci Research社のヘルスケア分野での最新刊レポート
本レポートと同じKEY WORD(therapeutics)の最新刊レポート
よくあるご質問TechSci Research社はどのような調査会社ですか?テックサイリサーチ(TechSci Research)は、カナダ、英国、インドに拠点を持ち、化学、IT、環境、消費財と小売、自動車、エネルギーと発電の市場など、多様な産業や地域を対象とした調査・出版活... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|